Aktienanalyse zu Filana Therapeutics Inc (FLNA)FLNAFilana Therapeutics Inc

Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. It operates in the Healthcare sector.

Filana Therapeutics is not a good buy right now due to its current price of $0.448, which is significantly below its 52-week high of $2.38, indicating a severe decline of 81.18% year-to-date. Additionally, the RSI is at a very low 16.907, suggesting the stock is oversold, but the negative momentum and lack of profitability, with a forward P/E of 151.5152 and consistent net losses, raise concerns. The main risk is the company's ongoing cash burn, with net income losses reaching -$44,224,000 in Q2 2025, which could impact its ability to fund operations and growth.